Lou Gehrigs disease Motor neuron disease
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. a. MND patients: definite, probable, probable-laboratory supported or possible ALS according to the El Escorial criteria (Brooks, 2000), PMA or PLS. b. Control subjects: no diagnosis of MND or ALS mimics and age- and gender-matched to patient groups, intact physical ability to take part in the experiment. c. Asymptomatic carriers: carriers of MND-related gene mutations with no neurological symptoms associated with MND. 2. Age:18 and older 3. Capable of performing active tests with their right hand; muscle strength should be above 3 on the medical research council (MRC) scale27. 4. Capable of thoroughly understanding the study information given; has signed the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria are for all participants: 1. a history of major head trauma or other neurological conditions that could affect cognition, 2. alcohol dependence syndrome, current use of neuroleptic medications or high dose psychoactive medication. 3. History of reaction or allergy to recording environments, equipment and the recording gels. 4. Tracheostomy, tracheostomal ventilation of any type, (non)-invasive ventilation. 5. Pregnancy. Further exclusion criteria for healthy controls and asymptomatic carriers: 6. History of neuromuscular, neurological or active psychiatric disease Further exclusion criteria for patients: 7. The presence of any active psychiatric disease, and any medical condition associated with neuropathy (e.g. diabetes). 8. Any history or presence of brain injury, epilepsy, psychiatric illness and other cerebral disease. 9. Any intoxication or medication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of MND.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A set of neuromuscular properties determined from the uniform examination protocol which is performed on the Wristalyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| A set of clinical scores of characteristic symptoms in MND, derived in neurological examination. | — |
Countries
Netherlands
Outcome results
None listed